首页 | 本学科首页   官方微博 | 高级检索  
     


Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor‐Positive/HER2‐Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter,Randomized, Placebo‐Controlled,Phase III Study (PALOMA‐3)
Authors:Sunil Verma  Cynthia Huang Bartlett  Patrick Schnell  Angela M. DeMichele  Sherene Loi  Jungsil Ro  Marco Colleoni  Hiroji Iwata  Nadia Harbeck  Massimo Cristofanilli  Ke Zhang  Alexandra Thiele  Nicholas C. Turner  Hope S. Rugo
Affiliation:1. University of Calgary, Alberta, Canada;2. Pfizer Inc., Collegeville, Pennsylvania, USA;3. Pfizer Inc., New York, New York, USA;4. University of Pennsylvania, Philadelphia, Pennsylvania, USA;5. Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;6. National Cancer Center, Goyang‐si, Republic of Korea;7. Istituto Europeo di Oncologia, Milan, Italy;8. Aichi Cancer Center Hospital, Nagoya, Japan;9. Brustzentrum der Universit?t München, Munich, Germany;10. Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, Illinois, USA;11. Pfizer Inc., San Diego, California, USA;12. Pfizer Inc., Cambridge, Massachusetts, USA;13. Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom;14. University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
Abstract:
Keywords:Cyclin‐dependent kinase 4  Cyclin‐dependent kinase 6  Palbociclib  Neutropenia
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号